US20050222649A1 - Method for treatment of aneurysms - Google Patents

Method for treatment of aneurysms Download PDF

Info

Publication number
US20050222649A1
US20050222649A1 US11/119,368 US11936805A US2005222649A1 US 20050222649 A1 US20050222649 A1 US 20050222649A1 US 11936805 A US11936805 A US 11936805A US 2005222649 A1 US2005222649 A1 US 2005222649A1
Authority
US
United States
Prior art keywords
energy
aneurysm
treatment
catheter
target tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US11/119,368
Other versions
US7912554B2 (en
Inventor
Leonilda Capuano
Daniel Nahon
Michael Urick
Willard Hennemann
Patrick Chauvet
Claudia Luckge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Cryocath LP
Original Assignee
Cryocath Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/964,264 external-priority patent/US6736809B2/en
Priority claimed from US10/839,766 external-priority patent/US20040249372A1/en
Priority to US11/119,368 priority Critical patent/US7912554B2/en
Application filed by Cryocath Technologies Inc filed Critical Cryocath Technologies Inc
Assigned to CRYOCATH TECHNOLOGIES INC. reassignment CRYOCATH TECHNOLOGIES INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: URICK, MICHAEL, CHAUVET, PATRICK, HENNEMANN, WILLARD W., LUCKGE, CLAUDIA, NAHON, DANIEL, CAPUANO, LEONILDA
Publication of US20050222649A1 publication Critical patent/US20050222649A1/en
Assigned to INVESTISSEMENT QUEBEC reassignment INVESTISSEMENT QUEBEC SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CRYOCATH TECHNOLOGIES, INC.
Assigned to CRYOCATH TECHNOLOGIES INC. reassignment CRYOCATH TECHNOLOGIES INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: INVESTISSEMENT QUEBEC
Assigned to MEDTRONIC CRYOCATH LP reassignment MEDTRONIC CRYOCATH LP ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CRYOCATH TECHNOLOGIES INC.
Publication of US7912554B2 publication Critical patent/US7912554B2/en
Application granted granted Critical
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0601Apparatus for use inside the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22001Angioplasty, e.g. PCTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22051Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for with an inflatable part, e.g. balloon, for positioning, blocking, or immobilisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053Mechanical features of the instrument of device
    • A61B2018/00059Material properties
    • A61B2018/00089Thermal conductivity
    • A61B2018/00095Thermal conductivity high, i.e. heat conducting
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053Mechanical features of the instrument of device
    • A61B2018/00214Expandable means emitting energy, e.g. by elements carried thereon
    • A61B2018/0022Balloons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00345Vascular system
    • A61B2018/00404Blood vessels other than those in or around the heart
    • A61B2018/00416Treatment of aneurisms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A61B2018/0212Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques using an instrument inserted into a body lumen, e.g. catheter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A61B2018/0231Characteristics of handpieces or probes
    • A61B2018/0262Characteristics of handpieces or probes using a circulating cryogenic fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/02Radiation therapy using microwaves
    • A61N5/04Radiators for near-field treatment
    • A61N5/045Radiators for near-field treatment specially adapted for treatment inside the body

Definitions

  • the present invention relates to a method and device for treating vascular defects such as aneurysms, dissections, arterio-venous malformation and vulnerable plaque, and in particular, to a method involving the use of a catheter and thermo-cryogenic, electromagnetic, and ultrasonic energy sources concomitantly with an additional treatment to treat tissue.
  • Aneurysms are distensions formed by the localized dilation of the wall of an artery, a vein, or the heart.
  • a “true” or common aneurysm results from the formation of a sac by the arterial wall, or tunica media, which remains unbroken, and may be associated with atherosclerosis.
  • a fissure in the wall of a blood vessel allows blood to escape into surrounding tissues and form a clot.
  • doctors typically monitor the inflammation and progression of aneurysms using devices known in the art such as MRI and CT scanners and by observation of known patient symptoms. Typically, however, early stage aneurysms do not warrant dangerous surgical procedures, even if minimally invasive, due to the associated morbidity risk. Accordingly, the doctors choose a “wait and see” approach. Because surgery for aneurysms is risky, the surgeon may wait for the aneurysm to expand to a certain size before operating, when the risk of complications exceeds the risk of surgery. Accordingly, it would be desirable to treat aneurysms upon early detection rather than wait until they progress to a stage that requires dangerous, expensive surgery, or become life-threatening conditions.
  • vascular dissections are similar to aneurysms in that the vessel wall integrity is compromised.
  • a dissection consists of a laceration of a portion of the vessel wall. Both dissections and lacerations are associated risks stemming from arterial disease.
  • vascular defects such as dissections or aneurysm formation, and arterio-venous malformation or vulnerable plaque.
  • a method for treating a vascular defect is disclosed.
  • a catheter having an energy-transfer element is positioned and disposed proximate a target tissue region including the vascular defect.
  • Energy is transferred between the energy-transfer element and the target tissue region.
  • the energy may be emitted as a treatment energy from the energy-transfer element, and further directed to be in part absorbed by the target tissue region.
  • the treatment energy may be any of the following group: visible light energy, laser light energy, ultrasonic periodic mechanical vibrational, or ultrasound, energy, and microwave or radiofrequency electromagnetic energy.
  • the energy-transfer element is a heat-absorbing device, and heat is transferred from the target tissue region to the heat-absorbing device.
  • the heat transfer element can include an expansion chamber, wherein a coolant is injected into the expansion chamber.
  • the treatment method may include providing energy transfer paired with an additional treatment method, including drug delivery, the use of an implanted medical device, a biological filler material, or an endovascular graft.
  • a method for thickening, strengthening, or increasing the density of a blood vessel wall.
  • a catheter is provided having an energy-transfer element. The catheter is positioned such that the energy-transfer element is disposed proximate the blood vessel wall. A flow of treatment energy is transferred between the energy-transfer element and the blood vessel wall.
  • a method for enhancing collagen production in blood vessels proximate a vascular defect.
  • Collagen inducing growth factors are injected into a target tissue region proximate the vascular defect.
  • a device having a discrete light energy-emitting element is provided. The element is disposed proximate to the target tissue region. The energy-emitting element is directed to emit light energy and to irradiate the target tissue region with said light energy. The collagen inducing growth factors are activated with the light energy.
  • a method for cryotreating vulnerable plaque.
  • the method provides for the treatment of plaque formed on an interior lumenal surface of a body or blood lumen.
  • a cooling device is positioned at the interior lumenal surface at a point proximate to a plaque formation.
  • the lumenal surface is cooled at the point proximate to the plaque formation to inhibit the progression of plaque formation in which the lumenal surface is cooled to a temperature of less than about zero degrees Celsius.
  • FIG. 1 is a cross-sectional view of a balloon catheter device disposed inside of a blood vessel proximate an aneurysm;
  • FIG. 2 is a cross-sectional view of a catheter with a cooling segment positioned proximate the arterial wall in an aneurysm;
  • FIG. 3 is a perspective view of a balloon-cuff catheter device for contact with an aneurysm outside the arterial wall;
  • FIG. 4 is a view of a catheter device using photodynamic energy disposed inside of a blood vessel proximate an aneurysm
  • FIG. 5 is a view of a catheter device using laser energy disposed inside of a blood vessel proximate an aneurysm
  • FIG. 6 is a view of a catheter device using sound energy disposed inside of a blood vessel proximate an aneurysm
  • FIG. 7 is a view of a catheter device using microwave energy disposed inside of a blood vessel proximate an aneurysm
  • FIG. 8 is a view of a catheter device using radio frequency energy disposed inside of a blood vessel proximate an aneurysm
  • FIG. 9 is a view of a catheter device disposed inside of a blood vessel proximate a dissection
  • FIG. 10 is a view of a catheter device having an energy-transfer element and delivering a compound inside of a blood vessel proximate an aneurysm;
  • FIG. 11 is a view of a catheter device having an energy-transfer element and delivering a mechanical intravascular device inside of a blood vessel proximate an aneurysm;
  • FIG. 12 is a view of a catheter device having an energy-transfer element and delivering an endovascular graft inside of a blood vessel proximate an aneurysm;
  • FIG. 13 is a view of a balloon catheter device inflated within a blood vessel to contact an area of vulnerable plaque.
  • vascular defect shall mean an aneurysm, a dissection, or vulnerable plaque as further described and set forth herein.
  • An aneurysm is typically characterized by a localized dilatation in a blood vessel, while a dissection occurs when a defect in the lining of a blood vessel allows an opening or tear to develop in the vessel wall.
  • Vascular or vulnerable plaque is typically caused by coronary artery disease, and involves the formation of plaque, a combination of cholesterol and cellular waste products that form on the interior wall of an artery. Eventually, the plaque deposit can develop a thin covering called a fibrous cap. With plaque progression, the vessel wall can experience inflammation, leading to the erosion of the fibrous cap. The erosion may cause the plaque cap to crack, allowing the underlying plaque elements to come in contact with the blood stream. Exposure of these elements to the blood stream can cause clot formation, leading to coronary artery occlusion, myocardial ischemia and infarction. This particular type of lipid-rich plaque, having active inflammation and the potential to erode the overlying fibrous cap, which in turn can lead to thrombosis and myocardial infarction is called unstable or vulnerable plaque.
  • Catheter based devices enable access to the weakened arterial wall around an aneurysm, a dissection or venerable plaque, are minimally invasive, and may be employed for a variety of diagnostic and therapeutic functions.
  • Localized application of cold temperatures to the blood vessel wall may serve to strengthen and thicken the distended and dilated tissue of an aneurysm, and make such tissue layers increasingly dense, as well as inhibit the progression of plaque formation. Accordingly, by applying such cold, or cryotreatment, to the aneurysm, dissection or vulnerable plaque site, the aneurysm, dissection or vulnerable plaque may be effectively treated without major surgery.
  • FIG. 1 illustrates a blood vessel and a device during a procedure for cryotreatment of an aneurysm.
  • a balloon catheter labelled generally as 10
  • the balloon catheter 10 includes a flexible, expandable membrane or balloon 13 coupled to a catheter tube 14 , wherein the catheter 10 is guided to the desired treatment site via a guidewire 15 .
  • the balloon catheter 10 is percutaneously inserted into the vasculature and advanced to the locus of the aneurysm 12 .
  • the specific size and shape of the balloon 13 and catheter tube 14 may be determined a priori in order to best fit the targeted artery or blood vessel where an aneurysm has formed.
  • the balloon 13 is thereby inflated to appose the inner walls of the blood vessel proximate the aneurysm 12 , so as to enable cryotreatment of the aneurysm 12 tissue.
  • the dilatation and apposition of the balloon 13 versus the inner walls of the aneurysm is not meant to dilate the blood vessel walls.
  • the device employed in this procedure uses a balloon-tipped catheter configured to receive the flow of a coolant, or cryogenic fluid, therein.
  • High-pressure coolant fluid is connected to the proximal section of the catheter tube 14 , which contains several tubes and lumens (not shown) adapted to contain the flow of coolant therein.
  • the coolant used may be any stable working fluid capable of being compressed to high pressure, pumped though small diameter devices, and expanded to produce endothermic cooling at a desired location. Examples of such coolants are nitrogen, nitrous oxide, or any conventionally used refrigerant.
  • the coolant may be in liquid, gaseous, or mixed phase form.
  • the flow system inside of the catheter may be either closed loop, wherein the injected coolant is returned to the source for recycling and re-entry into the device, or open loop, wherein the coolant is pumped through the device only once, whereupon it exits outside the body and is discarded.
  • the coolant flows through the catheter tube 14 and is injected, generally along coolant flow lines F, into the balloon 13 at the distal tip of the catheter 10 , whereupon the balloon 13 expands as the coolant is both vaporized and expanded inside the balloon.
  • the combined evaporation and expansion of the coolant creates endothermic cooling in the near field of the balloon 13 .
  • the process is endothermic in that heat, or thermal energy, is absorbed by the balloon 13 , and flow of coolant therein, from the surrounding environment: the aneurysm and targeted tissue of the blood vessel wall which forms the aneurysm.
  • This cooling draws heat from the adjacent aneurysm tissue in the coolant flow inside of balloon 13 , thereby cooling the aneurysm tissue to temperatures in the range of +20 to ⁇ 20 degrees Centigrade.
  • the particular shape of the expanded balloon 13 may be predetermined by the use of a preformed balloon membrane, a memory retaining material, or other structural attribute wherein the expanded balloon 13 is configured to form a particular shape, yet also remain somewhat conformable.
  • the balloon 13 may also be totally conformable, such that the expanded membrane fits to conform to the particular contours of the blood vessel wall of the aneurysm 12 , for optimal contact therewith.
  • the distal tip of the catheter 10 may also include multiple expandable membranes or chambers (not shown), wherein different injection fluids are pumped into separate chambers within a single membrane, or multiple outer membranes.
  • One injection fluid may be used to expand a first chamber, while another cooling fluid may be used to create endothermic cooling in the same or another chamber, as discussed above.
  • Any tissue near or adjacent to the balloon and flow of coolant therein may be cooled to temperatures below body temperature.
  • the duration of cooling may vary from 15 seconds to up to 20 minutes, depending on the application, and the particular aneurysm targeted.
  • Part or the entire surface of the balloon may be specially treated or affixed with heat conductive elements to create a pattern of cooling on the tissue surfaces targeted.
  • An example of such an endovascular balloon catheter used to cold treat tissues is disclosed in U.S. Pat. No. 6,283,959 B1, the entirety of which is incorporated herein by reference.
  • the tissue forming the aneurysm 12 is thus cold-treated by the catheter device 10 , whereupon the balloon 13 is contracted or evacuated, and withdrawn from the treatment site.
  • cryotreatment of aneurysm tissue in the prescribed time and temperature ranges discussed above may, among other effects, stimulate a tissue response which results in myointimal thickening of the blood vessel wall and anvential tissue. This thickening helps to minimize the incidence of aneurysm rupture, which can be fatal. Cryotreatment may also result in reparative regeneration of the endothelium, in addition to accelerated myointimal thickening. These overall effects serve to treat and possibly reverse the formation of an aneurysm, leading to significant therapeutic results.
  • Aneurysmal enlargement results in part from degradation of the extracellular matrix and other structural elements of the blood vessel wall. This in turn is related to an increased activity of proteolytic enzymes such as collagenase and elastase, resulting in destruction of collagen and elastin forming the blood vessel wall.
  • Macrophages and inflammatory cells may also be sources of enzymes, which have a capacity to degrade all the major connective tissues forming the blood vessel wall, including collagen and elastin, all of which contribute to aneurysms.
  • the application of cold temperatures to such tissues may slow or retard the action of such macrophages, proteolytic enzymes, thus diminishing the destruction of collagen and elastin that is vital to the structural integrity of the blood vessel wall. In such a way, cryotreatment may effectively treat aneurysms.
  • aneurysms also exhibit the synthesis and accumulation of new collagen and elastin in the expanding aorta.
  • these newly synthesized proteins often lack the intricate fibrillar structure and mature cross-linking necessary to maintain the normal tensile strength of the cellular matrix of the aortic wall.
  • Cryotreatment of such areas may show the ability to compensate for such an effect, allowing the enlarged aortic wall to retain its normal extra-cellular matrix characteristics.
  • the application of the cryotreatment to vulnerable plaque sites reduces the inflammation of the blood vessel while increasing the collagen synthesis, to effectively treat vascular plaque.
  • the balloon 13 as used for cryotreatment is an apposition device, and not a dilatation device. Accordingly, the strength of materials forming the balloon 13 itself, as well as the fluid pressures therein, are generally not required to be as high as a conventional blood vessel-dilating angioplasty balloon.
  • the catheter 10 itself may also be combined with an injection element, wherein a therapeutic drug or medication is infused in the target area around the aneurysm 12 in conjunction with the use of the balloon 13 to effect cryotreatment.
  • FIG. 2 shows an endovascular catheter 20 disposed inside of a blood vessel 21 near an aneurysm 22 .
  • the catheter 20 includes a catheter tube 23 having a cooling segment 24 disposed at its distal end portion.
  • the catheter 20 may include one or more injection lumens 26 , as well as several tubes and lumens (not shown) adapted to contain the flow of coolant therein.
  • the distal end of the catheter 20 is shown in a substantially linear or straight configuration, the distal tip can be configured or commanded to assume an annular or helical shape.
  • the catheter 20 is percutaneously inserted into the vasculature and advanced to the aneurysm site 22 .
  • a guidewire, rapid-exchange system, or other catheter positioning device may be employed to position the catheter tip at the desired location.
  • Coolant is injected into the catheter 20 via injection lumen 26 , and flows through to the distal tip of the catheter, which contains the cooling segment 24 .
  • the cooling segment 24 is any heat conductive element, which defines a closed volume expansion chamber 25 , wherein coolant may be expanded to low temperatures after it exits the injection lumen 26 .
  • the coolant which may be in mixed liquid or gaseous phase, is injected into the expansion chamber 25 , whereby it undergoes both evaporative cooling through a change in phase from liquid to gas, and expansive cooling through a Joule-Thomson throttling process, similar to the those thermodynamic changes discussed with respect to the balloon catheter device 10 of FIG. 1 .
  • these gas-dynamic processes are generally endothermic with respect to the surrounding environment, in that heat is drawn from the tissue forming the surrounding aneurysm 22 so as to cool such tissue to temperatures below normal human body temperature, and indeed below the freezing point of water and beyond.
  • the strength of cooling may be controllably varied by the user by controlling the pressure and flow of coolant in the catheter device.
  • the size and particular shape of the cooling segment 24 may be varied to best fit the contours of the particular aneurysm to be treated, such as a berry aneurysm in the brain, a saccular aortic aneurysm just above the heart, or a fusiform aneurysm in the lower aorta, as is illustrated in FIG. 1 .
  • FIGS. 1 and 2 illustrate an approach to treating an aneurysm from within a blood vessel
  • FIG. 3 shows another embodiment wherein an aneurysm can be approached from the exterior of a blood vessel.
  • the device can be a fixed diameter catheter, a probe, an inflatable device, which is applied to the surface of the aneurysm, or even a fixed, compliant, or inflatable cuff which partially or completely encircles the vessel in the location of the aneurysm, as shown in FIG. 3 .
  • FIG. 3 illustrates a cryotreatment device 30 , externally disposed adjacent to or proximate a blood vessel 31 having an aneurysm 32 .
  • the device 30 includes a coolant source element 33 having an expandable, inflatable membrane, such as the cuff 34 shown in FIG. 3 .
  • the cuff 34 may have a U-shape in order to conformably fit around one hemisphere of a rounded aneurysm 32 , as shown in FIG. 3 .
  • the cuff 34 may be highly compliant and conformable such that when apposed against an aneurysm of any shape, the outer surface of such cuff 34 conformably rests in contact with such surface and envelops a significant surface area of the aneurysm.
  • the device 30 includes at least one injection lumen (not shown) in the source element 33 to carry the flow of coolant into the interior of cuff 34 .
  • the coolant may then be injected into the cuff 34 , such as along the flow lines F shown in FIG. 3 .
  • the cuff 34 is inflatably expandable by the action of a gas or liquid which may include the coolant or a completely separate source.
  • the cuff 34 may be a preformed balloon membrane, or may include a memory retaining material or other structural attribute wherein the expanded form is configured to form a particular shape, yet also remain somewhat conformable.
  • the cuff 34 is externally applied in proximity to, or in apposition against, the desired aneurysm treatment site, such as in the direction of arrows A shown in FIG. 3 .
  • the flow of coolant in the cuff 34 endothermically cools the target tissue of the aneurysm 32 , in accordance with the previous two embodiments of the present invention.
  • the flow of coolant may result in the target tissue being cooled to a temperature between about 0° C. to about ⁇ 200° C. This approach may be combined with conventional surgery to treat the aneurysm, wherein the cold treatment of the arterial wall is used with other treatment techniques and therapies.
  • non-thermal energy sources may be used to treat the blood vessel wall proximate an aneurysm, including, among others, visible light energy of a particular wavelength, laser light energy, ultrasound, and microwave and radiofrequency electromagnetic energy.
  • all such sources of “treatment” energy may have beneficial effects in counteracting the disorders of collagen and elastin synthesis characteristic of aneurysm formation, in addition to being able to create lesions and scar tissue within the walls of blood vessels such as the aorta.
  • FIG. 4 illustrates a catheter 40 disposed inside a blood vessel 11 proximate an aneurysm 12 .
  • the catheter 40 includes an energy-transfer device or element 42 disposed at its distal end portion 43 .
  • an “energy-transfer” device shall mean any device that transfers energy between the device and its environment, wherein energy may flow either to or from the device.
  • an energy-transfer device may be either an energy-emitting device or an energy-absorbing device.
  • One example of an energy-absorbing device would be the catheter 10 with balloon 13 in the embodiment shown in FIG. 1 , the catheter 20 with cooling segment 24 in the embodiment shown in FIG. 2 , or the cryotreatment device 30 with source element 33 and cuff 34 in the embodiment shown in FIG. 3 .
  • the energy-transfer device 42 includes (not shown) a suitable device for emitting energy (labelled in FIG. 4 as dashed lines 45 ) in the form of waves or particles flowing from the distal end portion 43 of catheter 40 towards the inner wall 48 of the blood vessel 11 proximate the aneurysm 12 .
  • a suitable device for emitting energy labelled in FIG. 4 as dashed lines 45
  • the cellular structure of the blood vessel 11 absorbs the energy 45 , thereby triggering various therapeutic reactions and treating the aneurysm 12 .
  • FIG. 4 illustrates the use of photodynamic visible light energy 45 to treat the aneurysm 12 .
  • Such light energy may be anywhere in the visible range, having a wavelength of between 300 to 800 nanometers, or may be tuned to a particular frequency.
  • Photodynamic light energy may be used in conjunction with various collagen inducing growth factors that are either systemically or locally injected into the vasculature and blood stream. When such light energy is thereafter used to irradiate the blood vessel 11 and aneurysm 12 , it triggers a reaction in the vasculature with the injected collagen inducing growth factors so as to delay or halt aneurysm formation. Examples of such collagen inducing growth factors are TGF-beta 1, which acts to regulate connective tissue growth factors.
  • wavelength of light which may be used for such a purpose, depends on the penetration required and the particular photosensitivity. Light penetration in turn increases with increasing wavelength.
  • a wavelength suitable for the methods described herein is approximately 500 nanometers, although other wavelengths may be equally well suited.
  • FIG. 5 illustrates the use of a laser light emitting energy source 52 disposed at the distal end portion 53 of a catheter 50 introduced into a blood vessel 11 proximate aneurysm 12 .
  • the laser light is emitted in the direction of one of the arrows 54 in FIG. 5 , and thus may be used to target a specific localized region of tissue.
  • the laser light emitting energy source 52 may be fitted with beam direction optics (not shown) to focus and steer the emitted beam in any direction around the distal end portion 53 of catheter 50 , as shown by the multi-directional arrows 54 .
  • the emitted laser light may be optically directed, using prisms or other optical elements, to be emitted in a diffuse, spherical, or other non-linear three-dimensional waveform to impinge on larger areas of the interior of blood vessel 11 proximate aneurysm 12 .
  • the laser light may be used to create both small, localized treatment areas as well as larger, circumferential lesions, as may be required.
  • the light emitted 54 by the laser light emitting energy source 52 can be accurately tuned to trigger exactly the desired response in the cells of the blood vessel 11 near the aneurysm 12 .
  • the distal end portion 53 of the catheter 50 may be easily positioned around the interior of the blood vessel 11 , such that the emitted laser light 54 is accurately spatially positioned to affect a specific target region of the aneurysm 12 .
  • the entire process may utilize varying laser wavelengths to achieve varying results.
  • the treatment desired is purely for biostimulus, involving effects, which have a lesser permanent effect on tissue. Other times the treatment desired is less mild and seeks to ablate tissue. Examples of the particular laser light wavelengths used for biostimulus are approximately 1,000 nanometers, while that used for ablation is in the neighborhood of approximately 1250 nanometers, as may be delivered by a YAG (Yttrium Aluminum Garnet) laser.
  • YAG Yttrium Aluminum Garnet
  • FIG. 6 shows an alternative embodiment of the present invention, wherein a catheter 60 is disposed inside of a blood vessel 11 proximate an aneurysm 12 , having an energy-emitting element 62 disposed at the distal end portion 64 of said catheter 60 .
  • the energy-emitting element includes a device, which generates periodic mechanical vibrations in the form of sound waves 66 .
  • sound waves 66 may be anywhere in the sonic, infrasonic, or ultrasonic range, both audible and non-audible.
  • ultrasonic energy is preferred to create the desired therapeutic effects on the aneurysm 12 .
  • the energy emitted by the energy-emitting element 62 propagates though the interior of the blood vessel, through any blood flow, which may be present (not shown) and impinges upon the aneurysm 12 . This in turn generates the desired therapeutic reactions in treating the aneurysm 12 .
  • FIG. 7 illustrates still another embodiment of the present invention, wherein a catheter 70 having an energy-emitting element 72 disposed at its distal end portion 74 is introduced into a blood vessel 11 proximate an aneurysm 12 .
  • electromagnetic energy (as labelled by waves 76 in FIG. 7 ) is emitted from the energy-emitting element 72 to irradiate the inner wall 48 of the blood vessel 11 around the aneurysm 12 .
  • the electromagnetic energy may take several forms and frequencies, including both microwave and radiofrequency waves.
  • RF waves significantly heat up the blood flow.
  • the energy 76 emitted from the energy-emitting element 72 is better suited to irradiate the aneurysm 12 as desired.
  • the use of microwave, ultrasound or laser light is advantageous over RF energy in that the former three forms of energy are not inhibited by blood flow, and may be readily conducted thereby.
  • FIG. 9 illustrates a catheter device as in the previously shown embodiments disposed inside a vessel proximate a dissection.
  • the catheter 90 having a treatment tip section 92 is positioned inside the vessel 93 proximate a dissection 95 .
  • the methods discussed hereinabove are thus applied to treat the tissue, or a tissue region, around and including the lacerated vessel wall of the dissection.
  • the therapeutic effects of the methods disclosed herein apply in much the same manner as with other vascular defects such as aneurysms.
  • cryogenic thermal cooling visible light energy, laser light energy, ultrasound, and microwave and radiofrequency electromagnetic energy
  • other treatments for vascular defects including the use of pharmaceutically active compounds, vaso-occlusive materials, as well as implanted medical devices such as coils, stents, or grafts.
  • Such combined treatments may be delivered to an aneurysm region by a single medical device, or alternatively, through separate medical instruments.
  • the treatments may be applied concurrently, sequentially, or cyclically within a predetermined time period.
  • FIG. 10 shows a step of an alternative method of the present invention, wherein a catheter 100 is disposed inside of a blood vessel 102 proximate an aneurysm 104 .
  • the catheter includes an energy-transfer element 106 disposed at the distal end portion and the energy-transfer element may employ any of the above-mentioned energies.
  • the method further may include the dispersion of a vaso-occlusive or pharmaceutically active compound 108 within a close proximity of the aneurysm or vascular defect, such as through a series of apertures 110 in the catheter.
  • a vaso-occlusive compound may include injectable fluids or suspensions, such as microfibrillar collagen, thrombogenic fluids, or polymeric compositions. After such introduction to a tissue site, the vaso-occlusive compounds form a substantially solid space-filling mass, which provides some relief of vessel wall pressure in the region of an aneurysm. Such agents are often introduced into the vasculature through a catheter and are known in the art. Alternatively, a pharmaceutically or biologically active compound may be introduced through the catheter to the region of the aneurysm, including, but not limited to anti-proliferative agents, anti-inflammatory agents, anti-mitotic agents, or anaesthetic agents.
  • FIG. 11 illustrates a step of still another alternative method of the present invention, wherein a catheter 112 having an energy-transfer element 114 disposed at its distal end portion is introduced into a blood vessel 116 proximate an aneurysm 118 , where energy-transfer treatment may be provided in addition to the delivery of a mechanical intravascular device 120 .
  • the mechanical device 120 may be delivered through a designated lumen 122 within the energy-transfer catheter, or through an additional medical device.
  • a typical mechanical intravascular device is a wire coil or braid, which can be introduced through a catheter in a stretched linear form, which then assumes an irregular shape upon discharge of the device from the end of the catheter.
  • the detached coil is intended to block or impede the flow path of blood into the aneurysm, resulting in the blood being forced past the defect.
  • implanted coils may enhance the formation of a clot within the aneurysm, thereby aiding in the prevention of rupture and providing for the eventual sealing of the aneurysm.
  • the mechanical intravascular device 120 may be coated with a pharmaceutically-active agent, providing a synergistic effect through both mechanically impeding flow into the aneurysm as well as providing drug therapy to the tissue region. By applying an energy-transfer treatment, the collagen content of the surrounding vessel may be increased, thereby enhancing tissue in-growth of the coil to reduce the probability of recanalization to the aneurysm.
  • a step of yet another method of the present invention provides a catheter 124 having an energy-transfer element 126 disposed at its distal end portion being introduced into a blood vessel 128 proximate an aneurysm 130 in addition to the placement of an endovascular graft 132 at the aneurysm tissue site.
  • Endovascular grafts commonly include a tubular collapsible mechanical framework that can be delivered by catheter to the aneurysm site.
  • the graft 132 may also have barb-like anchors that fasten the graft to the walls of the vessel.
  • the endovascular graft 132 is intended to exclude blood flow from reaching the aneurysm while reinforcing the surrounding wall of the vessel, and such endovascular grafts are known in the art.
  • an energy-transfer treatment By applying an energy-transfer treatment, the collagen content of the surrounding vessel may be increased, thereby enhancing the attachment of the vascular graft.
  • the energy-transfer treatment may be applied to side branch vasculature to induce stenosis and mitigate backflow into the aneurysm, further enhancing the ability of an implanted graft to seal the aneurysm and isolate the defect from blood flow.
  • a vessel region 140 treated with a balloon catheter 142 and the balloon catheter 142 is infused with a cryogenic fluid and maintained in contact with tissue for a period of time as described above with respect to the cryotreatment of an aneurysm.
  • a balloon catheter is useful in situations where occlusion reduction is necessary and/or where a large area is being treated. In the latter case, the large contact area provided between the outer balloon surface and the vascular wall inner surface makes thermal energy transfer more efficient.
  • a balloon dilated region of a vessel is cooled prior to implantation of a vascular stent.
  • the combination of the energy-transfer treatment with the additional treatment methods may be applied to a tissue region at substantially the same time through a single medical device.
  • the treatment combinations may be applied sequentially, that is to say, one treatment followed by another treatment shortly thereafter, i.e., in a single medical procedure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Surgical Instruments (AREA)

Abstract

A method is disclosed for treating an aneurysm or vascular defect by cooling a target tissue region of the aneurysm or vascular defect to a temperature below body temperature for a preselected time period. The method entails thickening, strengthening, or increasing the density of a blood vessel wall by cooling the blood vessel wall with a cryogenically cooled device. The method also includes irradiating the inner wall of a blood vessel around an aneurysm or vascular defect with various forms of energy to delay or halt aneurysm or vascular defect formation. An energy-emitting element is disposed on the distal end portion of a catheter device to be disposed proximate the aneurysm. Various forms of energy, including visible light energy, laser light energy, ultrasound, microwave and radiofrequency sources may be used to irradiate and treat the aneurysm. In addition, the method may include irradiating a tissue site concomitantly with other treatments, including the delivery of vaso-occlusive compounds, mechanical intravascular devices, or an endovascular graft to the target tissue region.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application is a continuation-in-part of pending U.S. patent application Ser. No. 10/839,766, filed May 5, 2004, entitled METHOD FOR TREATMENT OF ANEURYSMS, which application is a continuation-in-part of U.S. patent application Ser. No. 09/964,264, filed Sep. 26, 2001, entitled METHOD AND DEVICE FOR TREATMENT OF ANEURYSMS, now allowed.
  • STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
  • n/a
  • FIELD OF THE INVENTION
  • The present invention relates to a method and device for treating vascular defects such as aneurysms, dissections, arterio-venous malformation and vulnerable plaque, and in particular, to a method involving the use of a catheter and thermo-cryogenic, electromagnetic, and ultrasonic energy sources concomitantly with an additional treatment to treat tissue.
  • BACKGROUND OF THE INVENTION
  • Aneurysms are distensions formed by the localized dilation of the wall of an artery, a vein, or the heart. An aneurysm balloons due to the pressure of blood flowing through an area weakened due to disease, injury, or congenital defect. A “true” or common aneurysm results from the formation of a sac by the arterial wall, or tunica media, which remains unbroken, and may be associated with atherosclerosis. In a “false” or dissecting aneurysm, usually caused by trauma, a fissure in the wall of a blood vessel allows blood to escape into surrounding tissues and form a clot.
  • Doctors typically monitor the inflammation and progression of aneurysms using devices known in the art such as MRI and CT scanners and by observation of known patient symptoms. Typically, however, early stage aneurysms do not warrant dangerous surgical procedures, even if minimally invasive, due to the associated morbidity risk. Accordingly, the doctors choose a “wait and see” approach. Because surgery for aneurysms is risky, the surgeon may wait for the aneurysm to expand to a certain size before operating, when the risk of complications exceeds the risk of surgery. Accordingly, it would be desirable to treat aneurysms upon early detection rather than wait until they progress to a stage that requires dangerous, expensive surgery, or become life-threatening conditions.
  • In addition to aneurysms, certain other vascular defects are of interest, such as a dissection. Vascular dissections are similar to aneurysms in that the vessel wall integrity is compromised. However a dissection consists of a laceration of a portion of the vessel wall. Both dissections and lacerations are associated risks stemming from arterial disease.
  • Therefore, it would be desirable to have a device, coupled with a minimally invasive method, to retard, arrest and even reverse, the processes that lead to vascular defects such as dissections or aneurysm formation, and arterio-venous malformation or vulnerable plaque.
  • SUMMARY OF THE INVENTION
  • A method for treating a vascular defect is disclosed. A catheter having an energy-transfer element is positioned and disposed proximate a target tissue region including the vascular defect. Energy is transferred between the energy-transfer element and the target tissue region. The energy may be emitted as a treatment energy from the energy-transfer element, and further directed to be in part absorbed by the target tissue region. The treatment energy may be any of the following group: visible light energy, laser light energy, ultrasonic periodic mechanical vibrational, or ultrasound, energy, and microwave or radiofrequency electromagnetic energy. Alternatively, the energy-transfer element is a heat-absorbing device, and heat is transferred from the target tissue region to the heat-absorbing device. The heat transfer element can include an expansion chamber, wherein a coolant is injected into the expansion chamber. In addition, the treatment method may include providing energy transfer paired with an additional treatment method, including drug delivery, the use of an implanted medical device, a biological filler material, or an endovascular graft.
  • In another embodiment, a method is provided for thickening, strengthening, or increasing the density of a blood vessel wall. A catheter is provided having an energy-transfer element. The catheter is positioned such that the energy-transfer element is disposed proximate the blood vessel wall. A flow of treatment energy is transferred between the energy-transfer element and the blood vessel wall.
  • In yet another embodiment, a method is provided for enhancing collagen production in blood vessels proximate a vascular defect. Collagen inducing growth factors are injected into a target tissue region proximate the vascular defect. A device having a discrete light energy-emitting element is provided. The element is disposed proximate to the target tissue region. The energy-emitting element is directed to emit light energy and to irradiate the target tissue region with said light energy. The collagen inducing growth factors are activated with the light energy.
  • In still yet another embodiment, a method is provided for cryotreating vulnerable plaque. The method provides for the treatment of plaque formed on an interior lumenal surface of a body or blood lumen. A cooling device is positioned at the interior lumenal surface at a point proximate to a plaque formation. The lumenal surface is cooled at the point proximate to the plaque formation to inhibit the progression of plaque formation in which the lumenal surface is cooled to a temperature of less than about zero degrees Celsius.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • A more complete understanding of the present invention, and the attendant advantages and features thereof, will be more readily understood by reference to the following detailed description when considered in conjunction with the accompanying drawings wherein:
  • FIG. 1 is a cross-sectional view of a balloon catheter device disposed inside of a blood vessel proximate an aneurysm;
  • FIG. 2 is a cross-sectional view of a catheter with a cooling segment positioned proximate the arterial wall in an aneurysm;
  • FIG. 3 is a perspective view of a balloon-cuff catheter device for contact with an aneurysm outside the arterial wall;
  • FIG. 4 is a view of a catheter device using photodynamic energy disposed inside of a blood vessel proximate an aneurysm;
  • FIG. 5 is a view of a catheter device using laser energy disposed inside of a blood vessel proximate an aneurysm;
  • FIG. 6 is a view of a catheter device using sound energy disposed inside of a blood vessel proximate an aneurysm;
  • FIG. 7 is a view of a catheter device using microwave energy disposed inside of a blood vessel proximate an aneurysm;
  • FIG. 8 is a view of a catheter device using radio frequency energy disposed inside of a blood vessel proximate an aneurysm;
  • FIG. 9 is a view of a catheter device disposed inside of a blood vessel proximate a dissection;
  • FIG. 10 is a view of a catheter device having an energy-transfer element and delivering a compound inside of a blood vessel proximate an aneurysm;
  • FIG. 11 is a view of a catheter device having an energy-transfer element and delivering a mechanical intravascular device inside of a blood vessel proximate an aneurysm;
  • FIG. 12 is a view of a catheter device having an energy-transfer element and delivering an endovascular graft inside of a blood vessel proximate an aneurysm; and
  • FIG. 13 is a view of a balloon catheter device inflated within a blood vessel to contact an area of vulnerable plaque.
  • DETAILED DESCRIPTION OF THE INVENTION
  • As used herein, a “vascular defect” shall mean an aneurysm, a dissection, or vulnerable plaque as further described and set forth herein. An aneurysm is typically characterized by a localized dilatation in a blood vessel, while a dissection occurs when a defect in the lining of a blood vessel allows an opening or tear to develop in the vessel wall.
  • Vascular or vulnerable plaque is typically caused by coronary artery disease, and involves the formation of plaque, a combination of cholesterol and cellular waste products that form on the interior wall of an artery. Eventually, the plaque deposit can develop a thin covering called a fibrous cap. With plaque progression, the vessel wall can experience inflammation, leading to the erosion of the fibrous cap. The erosion may cause the plaque cap to crack, allowing the underlying plaque elements to come in contact with the blood stream. Exposure of these elements to the blood stream can cause clot formation, leading to coronary artery occlusion, myocardial ischemia and infarction. This particular type of lipid-rich plaque, having active inflammation and the potential to erode the overlying fibrous cap, which in turn can lead to thrombosis and myocardial infarction is called unstable or vulnerable plaque.
  • Catheter based devices enable access to the weakened arterial wall around an aneurysm, a dissection or venerable plaque, are minimally invasive, and may be employed for a variety of diagnostic and therapeutic functions. Localized application of cold temperatures to the blood vessel wall may serve to strengthen and thicken the distended and dilated tissue of an aneurysm, and make such tissue layers increasingly dense, as well as inhibit the progression of plaque formation. Accordingly, by applying such cold, or cryotreatment, to the aneurysm, dissection or vulnerable plaque site, the aneurysm, dissection or vulnerable plaque may be effectively treated without major surgery.
  • FIG. 1 illustrates a blood vessel and a device during a procedure for cryotreatment of an aneurysm. In FIG. 1, a balloon catheter, labelled generally as 10, is disposed inside of a blood vessel 11 proximate to an aneurysm 12. The balloon catheter 10 includes a flexible, expandable membrane or balloon 13 coupled to a catheter tube 14, wherein the catheter 10 is guided to the desired treatment site via a guidewire 15. In this procedure, the balloon catheter 10 is percutaneously inserted into the vasculature and advanced to the locus of the aneurysm 12. The specific size and shape of the balloon 13 and catheter tube 14 may be determined a priori in order to best fit the targeted artery or blood vessel where an aneurysm has formed. The balloon 13 is thereby inflated to appose the inner walls of the blood vessel proximate the aneurysm 12, so as to enable cryotreatment of the aneurysm 12 tissue.
  • However, contrary to conventional angioplasty procedures, the dilatation and apposition of the balloon 13 versus the inner walls of the aneurysm is not meant to dilate the blood vessel walls. Rather, the device employed in this procedure uses a balloon-tipped catheter configured to receive the flow of a coolant, or cryogenic fluid, therein. High-pressure coolant fluid is connected to the proximal section of the catheter tube 14, which contains several tubes and lumens (not shown) adapted to contain the flow of coolant therein. The coolant used may be any stable working fluid capable of being compressed to high pressure, pumped though small diameter devices, and expanded to produce endothermic cooling at a desired location. Examples of such coolants are nitrogen, nitrous oxide, or any conventionally used refrigerant. The coolant may be in liquid, gaseous, or mixed phase form. The flow system inside of the catheter may be either closed loop, wherein the injected coolant is returned to the source for recycling and re-entry into the device, or open loop, wherein the coolant is pumped through the device only once, whereupon it exits outside the body and is discarded.
  • The coolant flows through the catheter tube 14 and is injected, generally along coolant flow lines F, into the balloon 13 at the distal tip of the catheter 10, whereupon the balloon 13 expands as the coolant is both vaporized and expanded inside the balloon. The combined evaporation and expansion of the coolant creates endothermic cooling in the near field of the balloon 13. The process is endothermic in that heat, or thermal energy, is absorbed by the balloon 13, and flow of coolant therein, from the surrounding environment: the aneurysm and targeted tissue of the blood vessel wall which forms the aneurysm. This cooling draws heat from the adjacent aneurysm tissue in the coolant flow inside of balloon 13, thereby cooling the aneurysm tissue to temperatures in the range of +20 to −20 degrees Centigrade.
  • The particular shape of the expanded balloon 13 may be predetermined by the use of a preformed balloon membrane, a memory retaining material, or other structural attribute wherein the expanded balloon 13 is configured to form a particular shape, yet also remain somewhat conformable. The balloon 13 may also be totally conformable, such that the expanded membrane fits to conform to the particular contours of the blood vessel wall of the aneurysm 12, for optimal contact therewith.
  • Alternatively, the distal tip of the catheter 10 may also include multiple expandable membranes or chambers (not shown), wherein different injection fluids are pumped into separate chambers within a single membrane, or multiple outer membranes. One injection fluid may be used to expand a first chamber, while another cooling fluid may be used to create endothermic cooling in the same or another chamber, as discussed above.
  • Any tissue near or adjacent to the balloon and flow of coolant therein may be cooled to temperatures below body temperature. The duration of cooling may vary from 15 seconds to up to 20 minutes, depending on the application, and the particular aneurysm targeted. Part or the entire surface of the balloon may be specially treated or affixed with heat conductive elements to create a pattern of cooling on the tissue surfaces targeted. An example of such an endovascular balloon catheter used to cold treat tissues is disclosed in U.S. Pat. No. 6,283,959 B1, the entirety of which is incorporated herein by reference. The tissue forming the aneurysm 12 is thus cold-treated by the catheter device 10, whereupon the balloon 13 is contracted or evacuated, and withdrawn from the treatment site.
  • The cryotreatment of aneurysm tissue in the prescribed time and temperature ranges discussed above may, among other effects, stimulate a tissue response which results in myointimal thickening of the blood vessel wall and anvential tissue. This thickening helps to minimize the incidence of aneurysm rupture, which can be fatal. Cryotreatment may also result in reparative regeneration of the endothelium, in addition to accelerated myointimal thickening. These overall effects serve to treat and possibly reverse the formation of an aneurysm, leading to significant therapeutic results.
  • Aneurysmal enlargement results in part from degradation of the extracellular matrix and other structural elements of the blood vessel wall. This in turn is related to an increased activity of proteolytic enzymes such as collagenase and elastase, resulting in destruction of collagen and elastin forming the blood vessel wall. Macrophages and inflammatory cells may also be sources of enzymes, which have a capacity to degrade all the major connective tissues forming the blood vessel wall, including collagen and elastin, all of which contribute to aneurysms. The application of cold temperatures to such tissues may slow or retard the action of such macrophages, proteolytic enzymes, thus diminishing the destruction of collagen and elastin that is vital to the structural integrity of the blood vessel wall. In such a way, cryotreatment may effectively treat aneurysms.
  • Furthermore, for large blood vessels such as the aorta, aneurysms also exhibit the synthesis and accumulation of new collagen and elastin in the expanding aorta. However, these newly synthesized proteins often lack the intricate fibrillar structure and mature cross-linking necessary to maintain the normal tensile strength of the cellular matrix of the aortic wall. Cryotreatment of such areas may show the ability to compensate for such an effect, allowing the enlarged aortic wall to retain its normal extra-cellular matrix characteristics. In a similar fashion, the application of the cryotreatment to vulnerable plaque sites reduces the inflammation of the blood vessel while increasing the collagen synthesis, to effectively treat vascular plaque.
  • In general, the balloon 13 as used for cryotreatment, is an apposition device, and not a dilatation device. Accordingly, the strength of materials forming the balloon 13 itself, as well as the fluid pressures therein, are generally not required to be as high as a conventional blood vessel-dilating angioplasty balloon.
  • The catheter 10 itself may also be combined with an injection element, wherein a therapeutic drug or medication is infused in the target area around the aneurysm 12 in conjunction with the use of the balloon 13 to effect cryotreatment.
  • In another procedure, a fixed diameter catheter device is used, as illustrated in FIG. 2. FIG. 2 shows an endovascular catheter 20 disposed inside of a blood vessel 21 near an aneurysm 22. The catheter 20 includes a catheter tube 23 having a cooling segment 24 disposed at its distal end portion. The catheter 20 may include one or more injection lumens 26, as well as several tubes and lumens (not shown) adapted to contain the flow of coolant therein. Although the distal end of the catheter 20 is shown in a substantially linear or straight configuration, the distal tip can be configured or commanded to assume an annular or helical shape. The catheter 20 is percutaneously inserted into the vasculature and advanced to the aneurysm site 22. A guidewire, rapid-exchange system, or other catheter positioning device may be employed to position the catheter tip at the desired location. Coolant is injected into the catheter 20 via injection lumen 26, and flows through to the distal tip of the catheter, which contains the cooling segment 24. The cooling segment 24 is any heat conductive element, which defines a closed volume expansion chamber 25, wherein coolant may be expanded to low temperatures after it exits the injection lumen 26. The coolant, which may be in mixed liquid or gaseous phase, is injected into the expansion chamber 25, whereby it undergoes both evaporative cooling through a change in phase from liquid to gas, and expansive cooling through a Joule-Thomson throttling process, similar to the those thermodynamic changes discussed with respect to the balloon catheter device 10 of FIG. 1. As with the balloon catheter device 10 embodiment above, these gas-dynamic processes are generally endothermic with respect to the surrounding environment, in that heat is drawn from the tissue forming the surrounding aneurysm 22 so as to cool such tissue to temperatures below normal human body temperature, and indeed below the freezing point of water and beyond. The strength of cooling may be controllably varied by the user by controlling the pressure and flow of coolant in the catheter device. The size and particular shape of the cooling segment 24 may be varied to best fit the contours of the particular aneurysm to be treated, such as a berry aneurysm in the brain, a saccular aortic aneurysm just above the heart, or a fusiform aneurysm in the lower aorta, as is illustrated in FIG. 1.
  • Although FIGS. 1 and 2 illustrate an approach to treating an aneurysm from within a blood vessel, FIG. 3 shows another embodiment wherein an aneurysm can be approached from the exterior of a blood vessel. In these procedures, the device can be a fixed diameter catheter, a probe, an inflatable device, which is applied to the surface of the aneurysm, or even a fixed, compliant, or inflatable cuff which partially or completely encircles the vessel in the location of the aneurysm, as shown in FIG. 3.
  • FIG. 3 illustrates a cryotreatment device 30, externally disposed adjacent to or proximate a blood vessel 31 having an aneurysm 32. The device 30 includes a coolant source element 33 having an expandable, inflatable membrane, such as the cuff 34 shown in FIG. 3. The cuff 34 may have a U-shape in order to conformably fit around one hemisphere of a rounded aneurysm 32, as shown in FIG. 3. Alternatively, the cuff 34 may be highly compliant and conformable such that when apposed against an aneurysm of any shape, the outer surface of such cuff 34 conformably rests in contact with such surface and envelops a significant surface area of the aneurysm.
  • The device 30 includes at least one injection lumen (not shown) in the source element 33 to carry the flow of coolant into the interior of cuff 34. The coolant may then be injected into the cuff 34, such as along the flow lines F shown in FIG. 3. As with the balloon catheter device 10 shown in FIG. 1, the cuff 34 is inflatably expandable by the action of a gas or liquid which may include the coolant or a completely separate source. The cuff 34 may be a preformed balloon membrane, or may include a memory retaining material or other structural attribute wherein the expanded form is configured to form a particular shape, yet also remain somewhat conformable.
  • Once inflated, the cuff 34 is externally applied in proximity to, or in apposition against, the desired aneurysm treatment site, such as in the direction of arrows A shown in FIG. 3. The flow of coolant in the cuff 34 endothermically cools the target tissue of the aneurysm 32, in accordance with the previous two embodiments of the present invention. The flow of coolant may result in the target tissue being cooled to a temperature between about 0° C. to about −200° C. This approach may be combined with conventional surgery to treat the aneurysm, wherein the cold treatment of the arterial wall is used with other treatment techniques and therapies.
  • In addition to the methods involving cryogenic thermal cooling, non-thermal energy sources may be used to treat the blood vessel wall proximate an aneurysm, including, among others, visible light energy of a particular wavelength, laser light energy, ultrasound, and microwave and radiofrequency electromagnetic energy. In addition to heat energy transferred by cooling, all such sources of “treatment” energy may have beneficial effects in counteracting the disorders of collagen and elastin synthesis characteristic of aneurysm formation, in addition to being able to create lesions and scar tissue within the walls of blood vessels such as the aorta.
  • FIG. 4 illustrates a catheter 40 disposed inside a blood vessel 11 proximate an aneurysm 12. The catheter 40 includes an energy-transfer device or element 42 disposed at its distal end portion 43. As used herein, an “energy-transfer” device shall mean any device that transfers energy between the device and its environment, wherein energy may flow either to or from the device. In this sense, an energy-transfer device may be either an energy-emitting device or an energy-absorbing device. One example of an energy-absorbing device would be the catheter 10 with balloon 13 in the embodiment shown in FIG. 1, the catheter 20 with cooling segment 24 in the embodiment shown in FIG. 2, or the cryotreatment device 30 with source element 33 and cuff 34 in the embodiment shown in FIG. 3.
  • In the embodiment illustrated in FIG. 4, the energy-transfer device 42 includes (not shown) a suitable device for emitting energy (labelled in FIG. 4 as dashed lines 45) in the form of waves or particles flowing from the distal end portion 43 of catheter 40 towards the inner wall 48 of the blood vessel 11 proximate the aneurysm 12. Upon contacting the inner wall 48, the cellular structure of the blood vessel 11 absorbs the energy 45, thereby triggering various therapeutic reactions and treating the aneurysm 12.
  • FIG. 4 illustrates the use of photodynamic visible light energy 45 to treat the aneurysm 12. Such light energy may be anywhere in the visible range, having a wavelength of between 300 to 800 nanometers, or may be tuned to a particular frequency. Photodynamic light energy may be used in conjunction with various collagen inducing growth factors that are either systemically or locally injected into the vasculature and blood stream. When such light energy is thereafter used to irradiate the blood vessel 11 and aneurysm 12, it triggers a reaction in the vasculature with the injected collagen inducing growth factors so as to delay or halt aneurysm formation. Examples of such collagen inducing growth factors are TGF-beta 1, which acts to regulate connective tissue growth factors. The particular wavelength of light, which may be used for such a purpose, depends on the penetration required and the particular photosensitivity. Light penetration in turn increases with increasing wavelength. One example of a wavelength suitable for the methods described herein is approximately 500 nanometers, although other wavelengths may be equally well suited.
  • In accordance with the preceding method, FIG. 5 illustrates the use of a laser light emitting energy source 52 disposed at the distal end portion 53 of a catheter 50 introduced into a blood vessel 11 proximate aneurysm 12. The laser light is emitted in the direction of one of the arrows 54 in FIG. 5, and thus may be used to target a specific localized region of tissue. The laser light emitting energy source 52 may be fitted with beam direction optics (not shown) to focus and steer the emitted beam in any direction around the distal end portion 53 of catheter 50, as shown by the multi-directional arrows 54. Alternatively, the emitted laser light may be optically directed, using prisms or other optical elements, to be emitted in a diffuse, spherical, or other non-linear three-dimensional waveform to impinge on larger areas of the interior of blood vessel 11 proximate aneurysm 12. Thus, the laser light may be used to create both small, localized treatment areas as well as larger, circumferential lesions, as may be required.
  • Because laser light is easily tuned to a precise frequency, the light emitted 54 by the laser light emitting energy source 52 can be accurately tuned to trigger exactly the desired response in the cells of the blood vessel 11 near the aneurysm 12. As illustrated by FIG. 5, the distal end portion 53 of the catheter 50 may be easily positioned around the interior of the blood vessel 11, such that the emitted laser light 54 is accurately spatially positioned to affect a specific target region of the aneurysm 12.
  • The entire process may utilize varying laser wavelengths to achieve varying results. Often the treatment desired is purely for biostimulus, involving effects, which have a lesser permanent effect on tissue. Other times the treatment desired is less mild and seeks to ablate tissue. Examples of the particular laser light wavelengths used for biostimulus are approximately 1,000 nanometers, while that used for ablation is in the neighborhood of approximately 1250 nanometers, as may be delivered by a YAG (Yttrium Aluminum Garnet) laser.
  • FIG. 6 shows an alternative embodiment of the present invention, wherein a catheter 60 is disposed inside of a blood vessel 11 proximate an aneurysm 12, having an energy-emitting element 62 disposed at the distal end portion 64 of said catheter 60. In this embodiment, the energy-emitting element includes a device, which generates periodic mechanical vibrations in the form of sound waves 66. Such sound waves 66 may be anywhere in the sonic, infrasonic, or ultrasonic range, both audible and non-audible. Although generally, ultrasonic energy is preferred to create the desired therapeutic effects on the aneurysm 12. As with the preceding embodiments, the energy emitted by the energy-emitting element 62 propagates though the interior of the blood vessel, through any blood flow, which may be present (not shown) and impinges upon the aneurysm 12. This in turn generates the desired therapeutic reactions in treating the aneurysm 12.
  • FIG. 7 illustrates still another embodiment of the present invention, wherein a catheter 70 having an energy-emitting element 72 disposed at its distal end portion 74 is introduced into a blood vessel 11 proximate an aneurysm 12. In this embodiment, electromagnetic energy (as labelled by waves 76 in FIG. 7) is emitted from the energy-emitting element 72 to irradiate the inner wall 48 of the blood vessel 11 around the aneurysm 12. The electromagnetic energy may take several forms and frequencies, including both microwave and radiofrequency waves.
  • All forms of energy as discussed herein trigger some thermal reactions with the blood flow inside the blood vessel 11. In particular, radiofrequency (RF) waves significantly heat up the blood flow. As such, it is desirable to position the catheter 70 as closely as possible to the inner wall 48 of blood vessel 11, as is illustrated in FIG. 8. In this fashion, the energy 76 emitted from the energy-emitting element 72 is better suited to irradiate the aneurysm 12 as desired. The use of microwave, ultrasound or laser light is advantageous over RF energy in that the former three forms of energy are not inhibited by blood flow, and may be readily conducted thereby.
  • Additionally, all of the foregoing methods may be equally applied to certain other vascular defects, including vascular dissections as well as aneurysms. FIG. 9 illustrates a catheter device as in the previously shown embodiments disposed inside a vessel proximate a dissection. The catheter 90, having a treatment tip section 92 is positioned inside the vessel 93 proximate a dissection 95. The methods discussed hereinabove are thus applied to treat the tissue, or a tissue region, around and including the lacerated vessel wall of the dissection. The therapeutic effects of the methods disclosed herein apply in much the same manner as with other vascular defects such as aneurysms.
  • In addition, the foregoing energy-transfer methods involving cryogenic thermal cooling, visible light energy, laser light energy, ultrasound, and microwave and radiofrequency electromagnetic energy may be combined with other treatments for vascular defects, including the use of pharmaceutically active compounds, vaso-occlusive materials, as well as implanted medical devices such as coils, stents, or grafts. Such combined treatments may be delivered to an aneurysm region by a single medical device, or alternatively, through separate medical instruments. Furthermore, the treatments may be applied concurrently, sequentially, or cyclically within a predetermined time period.
  • FIG. 10 shows a step of an alternative method of the present invention, wherein a catheter 100 is disposed inside of a blood vessel 102 proximate an aneurysm 104. The catheter includes an energy-transfer element 106 disposed at the distal end portion and the energy-transfer element may employ any of the above-mentioned energies. In addition to treating the aneurysm tissue region through energy-transfer, the method further may include the dispersion of a vaso-occlusive or pharmaceutically active compound 108 within a close proximity of the aneurysm or vascular defect, such as through a series of apertures 110 in the catheter. A vaso-occlusive compound may include injectable fluids or suspensions, such as microfibrillar collagen, thrombogenic fluids, or polymeric compositions. After such introduction to a tissue site, the vaso-occlusive compounds form a substantially solid space-filling mass, which provides some relief of vessel wall pressure in the region of an aneurysm. Such agents are often introduced into the vasculature through a catheter and are known in the art. Alternatively, a pharmaceutically or biologically active compound may be introduced through the catheter to the region of the aneurysm, including, but not limited to anti-proliferative agents, anti-inflammatory agents, anti-mitotic agents, or anaesthetic agents.
  • FIG. 11 illustrates a step of still another alternative method of the present invention, wherein a catheter 112 having an energy-transfer element 114 disposed at its distal end portion is introduced into a blood vessel 116 proximate an aneurysm 118, where energy-transfer treatment may be provided in addition to the delivery of a mechanical intravascular device 120. The mechanical device 120 may be delivered through a designated lumen 122 within the energy-transfer catheter, or through an additional medical device. A typical mechanical intravascular device is a wire coil or braid, which can be introduced through a catheter in a stretched linear form, which then assumes an irregular shape upon discharge of the device from the end of the catheter. The detached coil is intended to block or impede the flow path of blood into the aneurysm, resulting in the blood being forced past the defect. Moreover, implanted coils may enhance the formation of a clot within the aneurysm, thereby aiding in the prevention of rupture and providing for the eventual sealing of the aneurysm. In addition, the mechanical intravascular device 120 may be coated with a pharmaceutically-active agent, providing a synergistic effect through both mechanically impeding flow into the aneurysm as well as providing drug therapy to the tissue region. By applying an energy-transfer treatment, the collagen content of the surrounding vessel may be increased, thereby enhancing tissue in-growth of the coil to reduce the probability of recanalization to the aneurysm.
  • Now referring to FIG. 12, a step of yet another method of the present invention provides a catheter 124 having an energy-transfer element 126 disposed at its distal end portion being introduced into a blood vessel 128 proximate an aneurysm 130 in addition to the placement of an endovascular graft 132 at the aneurysm tissue site. Endovascular grafts commonly include a tubular collapsible mechanical framework that can be delivered by catheter to the aneurysm site. Moreover, the graft 132 may also have barb-like anchors that fasten the graft to the walls of the vessel. The endovascular graft 132 is intended to exclude blood flow from reaching the aneurysm while reinforcing the surrounding wall of the vessel, and such endovascular grafts are known in the art. By applying an energy-transfer treatment, the collagen content of the surrounding vessel may be increased, thereby enhancing the attachment of the vascular graft. Moreover, the energy-transfer treatment may be applied to side branch vasculature to induce stenosis and mitigate backflow into the aneurysm, further enhancing the ability of an implanted graft to seal the aneurysm and isolate the defect from blood flow.
  • An alternate embodiment, as shown in FIG. 13, a vessel region 140 treated with a balloon catheter 142 and the balloon catheter 142 is infused with a cryogenic fluid and maintained in contact with tissue for a period of time as described above with respect to the cryotreatment of an aneurysm. A balloon catheter is useful in situations where occlusion reduction is necessary and/or where a large area is being treated. In the latter case, the large contact area provided between the outer balloon surface and the vascular wall inner surface makes thermal energy transfer more efficient. In another exemplary procedure, a balloon dilated region of a vessel is cooled prior to implantation of a vascular stent.
  • As stated above, the combination of the energy-transfer treatment with the additional treatment methods may be applied to a tissue region at substantially the same time through a single medical device. Alternatively, the treatment combinations may be applied sequentially, that is to say, one treatment followed by another treatment shortly thereafter, i.e., in a single medical procedure.
  • It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described herein above. In addition, unless mention was made above to the contrary, it should be noted that all of the accompanying drawings are not to scale. A variety of modifications and variations are possible in light of the above teachings without departing from the scope and spirit of the invention, which is limited only by the following claims.

Claims (24)

1. A method for treating a vascular defect, comprising the steps of:
providing a catheter having an energy-transfer element,
positioning said catheter and disposing said energy-transfer element proximate a target tissue region including the vascular defect,
transferring energy between the energy-transfer element and the target tissue region;
providing a second treatment proximate a target tissue region including the vascular defect.
2. The method of claim 1, further comprising the steps of:
emitting a treatment energy from the energy-transfer element, and
directing said treatment energy to be in part absorbed by said target tissue region.
3. The method of claim 2, wherein the step of emitting a treatment energy comprises emitting visible light energy, and the step of directing said treatment energy comprises directing visible light energy.
4. The method of claim 2, wherein the step of emitting a treatment energy comprises emitting laser light energy, and the step of directing said treatment energy comprises directing laser light energy.
5. The method of claim 2, wherein the step of emitting a treatment energy comprises emitting ultrasonic periodic mechanical vibrational energy, and the step of directing said treatment energy comprises directing ultrasonic periodic mechanical vibrational energy.
6. The method of claim 2, wherein the step of emitting a treatment energy comprises emitting microwave electromagnetic energy, and the step of directing said treatment energy comprises directing microwave electromagnetic energy.
7. The method of claim 2, wherein the step of emitting a treatment energy comprises emitting radiofrequency electromagnetic energy, and the step of directing said treatment energy comprises directing radiofrequency electromagnetic energy.
8. The method of claim 2, wherein the catheter comprises proximal and distal end portions, said energy-emitting element being disposed on the distal end portion of said catheter.
9. The method of claim 1, wherein the energy-transfer element is a heat-absorbing device, and further comprising the steps of:
transferring heat from the target tissue region to the heat-absorbing device.
10. The method of claim 9, wherein the heat transfer device includes an expansion chamber, and further comprising the steps of:
injecting a coolant into the expansion chamber.
11. The method of claim 9, wherein transferring heat results in the target tissue region being cooled to a temperature between substantially about 0° C. to about −200° C.
12. The method of claim 1, wherein the second treatment includes delivering a vaso-occlusive compound to the target tissue region.
13. The method of claim 1, wherein the second treatment includes delivering a pharmaceutically-active compound to the target tissue region.
14. The method of claim 1, wherein the second treatment includes delivering a mechanical intravascular device to the target tissue region.
15. The method of claim 14, wherein the mechanical intravascular device is a wire coil.
16. The method of claim 14, wherein the mechanical intravascular device is a wire braid.
17. The method of claim 14, wherein the mechanical intravascular device is an intravascular stent.
18. The method of claim 1, wherein the second treatment includes delivering an endovascular graft to the target tissue region.
19. The method of claim 1, wherein the step of providing a second treatment is performed concomitantly with the step of transferring energy.
20. The method of claim 1, wherein the step of providing a second treatment is performed sequentially within a predetermined time period of the step of transferring energy.
21. The method of claim 1, wherein the vascular defect is an aneurysm.
22. The method of claim 1, wherein the vascular defect is a dissection.
23. The method of claim 1, wherein the vascular defect is vulnerable plaque.
24. The method of claim 1, wherein the vascular defect is an arterio-venous malformation.
US11/119,368 2001-09-26 2005-04-29 Method for treatment of aneurysms Expired - Fee Related US7912554B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/119,368 US7912554B2 (en) 2001-09-26 2005-04-29 Method for treatment of aneurysms

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/964,264 US6736809B2 (en) 2001-09-26 2001-09-26 Method and device for treatment of aneurysms
US10/839,766 US20040249372A1 (en) 2001-09-26 2004-05-05 Method for treatment of aneurysms
US11/119,368 US7912554B2 (en) 2001-09-26 2005-04-29 Method for treatment of aneurysms

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/839,766 Continuation-In-Part US20040249372A1 (en) 2001-09-26 2004-05-05 Method for treatment of aneurysms

Publications (2)

Publication Number Publication Date
US20050222649A1 true US20050222649A1 (en) 2005-10-06
US7912554B2 US7912554B2 (en) 2011-03-22

Family

ID=46304459

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/119,368 Expired - Fee Related US7912554B2 (en) 2001-09-26 2005-04-29 Method for treatment of aneurysms

Country Status (1)

Country Link
US (1) US7912554B2 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004961A1 (en) * 2004-11-03 2007-01-04 Case Brian C Methods for modifying vascular vessel walls
US20070135887A1 (en) * 2005-12-12 2007-06-14 Siemensaktiengesellschaft Catheter device for treating a block-age of a vessel
US20080033341A1 (en) * 2006-08-04 2008-02-07 Bay Holdings Ltd. Methods and devices for reducing or blocking blood flow to a selected blood vessel or part thereof
US20090036823A1 (en) * 2007-07-30 2009-02-05 Lepivert Patrick Fluid flowing device and method for tissue diagnosis or therapy
WO2009048390A1 (en) * 2007-10-11 2009-04-16 Milux Holding Sa System and method for thermal treatment of hypertension, hypotension or aneurysm
US7662177B2 (en) 2006-04-12 2010-02-16 Bacoustics, Llc Apparatus and methods for pain relief using ultrasound waves in combination with cryogenic energy
US20100274178A1 (en) * 2007-07-30 2010-10-28 Lepivert Patrick Fluid flowing device and method for tissue diagnosis or therapy
US20110171181A1 (en) * 2004-12-07 2011-07-14 Case Brian C Methods for modifying vascular vessel walls
US20120197244A1 (en) * 2011-01-31 2012-08-02 Cedars-Sinai Medical Center Treatment for aneurysm
US20120265188A1 (en) * 2011-04-13 2012-10-18 Cryotherapeutics Gmbh Plaque Stabilisation Using Cryoenergy
US20130035751A1 (en) * 2010-02-08 2013-02-07 Endospan Ltd. Thermal energy application for prevention and management of endoleaks in stent-grafts
US9254209B2 (en) 2011-07-07 2016-02-09 Endospan Ltd. Stent fixation with reduced plastic deformation
US9427339B2 (en) 2011-10-30 2016-08-30 Endospan Ltd. Triple-collar stent-graft
US9486341B2 (en) 2011-03-02 2016-11-08 Endospan Ltd. Reduced-strain extra-vascular ring for treating aortic aneurysm
US9526638B2 (en) 2011-02-03 2016-12-27 Endospan Ltd. Implantable medical devices constructed of shape memory material
US9668892B2 (en) 2013-03-11 2017-06-06 Endospan Ltd. Multi-component stent-graft system for aortic dissections
US9839510B2 (en) 2011-08-28 2017-12-12 Endospan Ltd. Stent-grafts with post-deployment variable radial displacement
US9993360B2 (en) 2013-01-08 2018-06-12 Endospan Ltd. Minimization of stent-graft migration during implantation
US10173027B2 (en) 2015-10-07 2019-01-08 Cook Medical Technologies Llc Methods, medical devices and kits for modifying the luminal profile of a body vessel
US10201413B2 (en) 2009-11-30 2019-02-12 Endospan Ltd. Multi-component stent-graft system for implantation in a blood vessel with multiple branches
AU2017202750B2 (en) * 2007-10-11 2019-05-23 Implantica Patent Ltd. System And Method For Thermal Treatment Of Hypertension, Hypotension Or Aneurysm
US10485684B2 (en) 2014-12-18 2019-11-26 Endospan Ltd. Endovascular stent-graft with fatigue-resistant lateral tube
US20200086108A1 (en) * 2010-08-19 2020-03-19 Electrocore, Inc. Vagal nerve stimulation to reduce inflammation associated with an aneurysm
US10603197B2 (en) 2013-11-19 2020-03-31 Endospan Ltd. Stent system with radial-expansion locking

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9440046B2 (en) 2002-04-04 2016-09-13 Angiodynamics, Inc. Venous insufficiency treatment method
US8864754B2 (en) 2002-07-10 2014-10-21 Angiodynamics, Inc. Device and method for endovascular treatment for causing closure of a blood vessel
US7458967B2 (en) * 2003-10-31 2008-12-02 Angiodynamics, Inc. Endovascular treatment apparatus and method
WO2012114333A1 (en) 2011-02-24 2012-08-30 Ilan Ben Oren Hybrid catheter for vascular intervention
US8992513B2 (en) 2011-06-30 2015-03-31 Angiodynamics, Inc Endovascular plasma treatment device and method of use
US9002454B2 (en) 2011-12-23 2015-04-07 Medtronic, Inc. Tracking pacing effectiveness based on waveform features
WO2017191644A1 (en) 2016-05-05 2017-11-09 Eximo Medical Ltd Apparatus and methods for resecting and/or ablating an undesired tissue
CA3133857A1 (en) 2019-03-20 2020-09-24 inQB8 Medical Technologies, LLC Aortic dissection implant
US12038322B2 (en) 2022-06-21 2024-07-16 Eximo Medical Ltd. Devices and methods for testing ablation systems

Citations (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108407A (en) * 1990-06-08 1992-04-28 Rush-Presbyterian St. Luke's Medical Center Method and apparatus for placement of an embolic coil
US5222938A (en) * 1989-09-15 1993-06-29 Interventional Thermodynamics, Inc. Method for thermal ablation of hollow body organs
US5275597A (en) * 1992-05-18 1994-01-04 Baxter International Inc. Percutaneous transluminal catheter and transmitter therefor
US5281215A (en) * 1992-04-16 1994-01-25 Implemed, Inc. Cryogenic catheter
US5370608A (en) * 1993-01-21 1994-12-06 Sahota; Harvinder Apparatus for minimizing restenosis
US5423807A (en) * 1992-04-16 1995-06-13 Implemed, Inc. Cryogenic mapping and ablation catheter
US5749894A (en) * 1996-01-18 1998-05-12 Target Therapeutics, Inc. Aneurysm closure method
US5817144A (en) * 1994-10-25 1998-10-06 Latis, Inc. Method for contemporaneous application OF laser energy and localized pharmacologic therapy
US5868735A (en) * 1997-03-06 1999-02-09 Scimed Life Systems, Inc. Cryoplasty device and method
US5885238A (en) * 1991-07-16 1999-03-23 Heartport, Inc. System for cardiac procedures
US5902299A (en) * 1997-07-29 1999-05-11 Jayaraman; Swaminathan Cryotherapy method for reducing tissue injury after balloon angioplasty or stent implantation
US5921954A (en) * 1996-07-10 1999-07-13 Mohr, Jr.; Lawrence G. Treating aneurysms by applying hardening/softening agents to hardenable/softenable substances
US5971979A (en) * 1997-12-02 1999-10-26 Odyssey Technologies, Inc. Method for cryogenic inhibition of hyperplasia
US6006755A (en) * 1994-06-24 1999-12-28 Edwards; Stuart D. Method to detect and treat aberrant myoelectric activity
US6012457A (en) * 1997-07-08 2000-01-11 The Regents Of The University Of California Device and method for forming a circumferential conduction block in a pulmonary vein
US6024740A (en) * 1997-07-08 2000-02-15 The Regents Of The University Of California Circumferential ablation device assembly
US6036697A (en) * 1998-07-09 2000-03-14 Scimed Life Systems, Inc. Balloon catheter with balloon inflation at distal end of balloon
US6051019A (en) * 1998-01-23 2000-04-18 Del Mar Medical Technologies, Inc. Selective organ hypothermia method and apparatus
US6126684A (en) * 1998-04-21 2000-10-03 The Regents Of The University Of California Indwelling heat exchange catheter and method of using same
US6129705A (en) * 1997-10-01 2000-10-10 Medtronic Ave, Inc. Drug delivery and gene therapy delivery system
US6228109B1 (en) * 1998-08-31 2001-05-08 Lily Chen Tu Methods for treating atherosclerosis and vulnerable plaques
US6241718B1 (en) * 1998-11-30 2001-06-05 Cryocath Technologies, Inc. Method for inhibiting restenosis
US20010032004A1 (en) * 1999-10-07 2001-10-18 Randell Werneth Inflatable heat transfer apparatus
US20020032430A1 (en) * 1999-12-07 2002-03-14 Xia Luo Method and system for treating stroke using hypothermia
US6375668B1 (en) * 1999-06-02 2002-04-23 Hanson S. Gifford Devices and methods for treating vascular malformations
US6386202B1 (en) * 1996-11-27 2002-05-14 The Regents Of The University Of California Method for treating ischemic brain stroke
US20020065542A1 (en) * 1998-04-22 2002-05-30 Ronald G. Lax Method and apparatus for treating an aneurysm
US6428563B1 (en) * 2000-01-21 2002-08-06 Radiant Medical, Inc. Heat exchange catheter with improved insulated region
US6468297B1 (en) * 1999-02-24 2002-10-22 Cryovascular Systems, Inc. Cryogenically enhanced intravascular interventions
US20020161351A1 (en) * 1998-09-01 2002-10-31 Samson Wilfred J. Method and apparatus for treating acute myocardial infarction with selective hypothermic perfusion
US6532387B1 (en) * 1999-03-26 2003-03-11 Kevin S. Marchitto Catheter for delivering electromagnetic energy for enhanced permeation of substances
US6576000B2 (en) * 2001-03-06 2003-06-10 Scimed Life Systems, Inc. Devices and methods for tissue repair
US6585689B1 (en) * 1997-12-08 2003-07-01 Cardeon Corporation Aortic catheter and methods for inducing cardioplegic arrest and for selective aortic perfusion

Patent Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5222938A (en) * 1989-09-15 1993-06-29 Interventional Thermodynamics, Inc. Method for thermal ablation of hollow body organs
US5108407A (en) * 1990-06-08 1992-04-28 Rush-Presbyterian St. Luke's Medical Center Method and apparatus for placement of an embolic coil
US5885238A (en) * 1991-07-16 1999-03-23 Heartport, Inc. System for cardiac procedures
US5423807A (en) * 1992-04-16 1995-06-13 Implemed, Inc. Cryogenic mapping and ablation catheter
US5281215A (en) * 1992-04-16 1994-01-25 Implemed, Inc. Cryogenic catheter
US5275597A (en) * 1992-05-18 1994-01-04 Baxter International Inc. Percutaneous transluminal catheter and transmitter therefor
US5370608A (en) * 1993-01-21 1994-12-06 Sahota; Harvinder Apparatus for minimizing restenosis
US5417653A (en) * 1993-01-21 1995-05-23 Sahota; Harvinder Method for minimizing restenosis
US6006755A (en) * 1994-06-24 1999-12-28 Edwards; Stuart D. Method to detect and treat aberrant myoelectric activity
US5817144A (en) * 1994-10-25 1998-10-06 Latis, Inc. Method for contemporaneous application OF laser energy and localized pharmacologic therapy
US5749894A (en) * 1996-01-18 1998-05-12 Target Therapeutics, Inc. Aneurysm closure method
US5921954A (en) * 1996-07-10 1999-07-13 Mohr, Jr.; Lawrence G. Treating aneurysms by applying hardening/softening agents to hardenable/softenable substances
US6386202B1 (en) * 1996-11-27 2002-05-14 The Regents Of The University Of California Method for treating ischemic brain stroke
US5868735A (en) * 1997-03-06 1999-02-09 Scimed Life Systems, Inc. Cryoplasty device and method
US6024740A (en) * 1997-07-08 2000-02-15 The Regents Of The University Of California Circumferential ablation device assembly
US6012457A (en) * 1997-07-08 2000-01-11 The Regents Of The University Of California Device and method for forming a circumferential conduction block in a pulmonary vein
US5902299A (en) * 1997-07-29 1999-05-11 Jayaraman; Swaminathan Cryotherapy method for reducing tissue injury after balloon angioplasty or stent implantation
US6129705A (en) * 1997-10-01 2000-10-10 Medtronic Ave, Inc. Drug delivery and gene therapy delivery system
US5971979A (en) * 1997-12-02 1999-10-26 Odyssey Technologies, Inc. Method for cryogenic inhibition of hyperplasia
US6585689B1 (en) * 1997-12-08 2003-07-01 Cardeon Corporation Aortic catheter and methods for inducing cardioplegic arrest and for selective aortic perfusion
US6051019A (en) * 1998-01-23 2000-04-18 Del Mar Medical Technologies, Inc. Selective organ hypothermia method and apparatus
US6126684A (en) * 1998-04-21 2000-10-03 The Regents Of The University Of California Indwelling heat exchange catheter and method of using same
US20020065542A1 (en) * 1998-04-22 2002-05-30 Ronald G. Lax Method and apparatus for treating an aneurysm
US6036697A (en) * 1998-07-09 2000-03-14 Scimed Life Systems, Inc. Balloon catheter with balloon inflation at distal end of balloon
US6228109B1 (en) * 1998-08-31 2001-05-08 Lily Chen Tu Methods for treating atherosclerosis and vulnerable plaques
US20020161351A1 (en) * 1998-09-01 2002-10-31 Samson Wilfred J. Method and apparatus for treating acute myocardial infarction with selective hypothermic perfusion
US6241718B1 (en) * 1998-11-30 2001-06-05 Cryocath Technologies, Inc. Method for inhibiting restenosis
US6468297B1 (en) * 1999-02-24 2002-10-22 Cryovascular Systems, Inc. Cryogenically enhanced intravascular interventions
US6532387B1 (en) * 1999-03-26 2003-03-11 Kevin S. Marchitto Catheter for delivering electromagnetic energy for enhanced permeation of substances
US6375668B1 (en) * 1999-06-02 2002-04-23 Hanson S. Gifford Devices and methods for treating vascular malformations
US20010032004A1 (en) * 1999-10-07 2001-10-18 Randell Werneth Inflatable heat transfer apparatus
US20020032430A1 (en) * 1999-12-07 2002-03-14 Xia Luo Method and system for treating stroke using hypothermia
US6428563B1 (en) * 2000-01-21 2002-08-06 Radiant Medical, Inc. Heat exchange catheter with improved insulated region
US6576000B2 (en) * 2001-03-06 2003-06-10 Scimed Life Systems, Inc. Devices and methods for tissue repair

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004961A1 (en) * 2004-11-03 2007-01-04 Case Brian C Methods for modifying vascular vessel walls
US8834351B2 (en) 2004-11-03 2014-09-16 Cook Medical Technologies Llc Methods for modifying vascular vessel walls
US7905826B2 (en) 2004-11-03 2011-03-15 Cook Incorporated Methods for modifying vascular vessel walls
US20110224484A1 (en) * 2004-11-03 2011-09-15 Case Brian C Methods for modifying vascular vessel walls
US10226256B2 (en) 2004-12-07 2019-03-12 Cook Medical Technologies Llc Methods for modifying vascular vessel walls
US8641776B2 (en) 2004-12-07 2014-02-04 Cook Biotech Incorporated Methods for modifying vascular vessel walls
US20110171181A1 (en) * 2004-12-07 2011-07-14 Case Brian C Methods for modifying vascular vessel walls
DE102005059261B4 (en) * 2005-12-12 2013-09-05 Siemens Aktiengesellschaft Catheter device for the treatment of a partial and / or complete vascular occlusion and X-ray device
US20070135887A1 (en) * 2005-12-12 2007-06-14 Siemensaktiengesellschaft Catheter device for treating a block-age of a vessel
US8167810B2 (en) 2005-12-12 2012-05-01 Siemens Aktiengesellschaft Catheter device for treating a blockage of a vessel
US7662177B2 (en) 2006-04-12 2010-02-16 Bacoustics, Llc Apparatus and methods for pain relief using ultrasound waves in combination with cryogenic energy
US20080033341A1 (en) * 2006-08-04 2008-02-07 Bay Holdings Ltd. Methods and devices for reducing or blocking blood flow to a selected blood vessel or part thereof
US9044212B2 (en) 2007-07-30 2015-06-02 Nuvue Therapeutics, Inc. Fluid flowing device and method for tissue diagnosis or therapy
WO2009018323A1 (en) * 2007-07-30 2009-02-05 Critical Care Innovations, Inc. Fluid flowing device and method for tissue diagnosis or therapy
US10251777B2 (en) 2007-07-30 2019-04-09 Nuvue Therapeutics, Inc. Fluid flowing device and method for tissue diagnosis or therapy
US8380299B2 (en) 2007-07-30 2013-02-19 Nuvue Therapeutics, Inc. Fluid flowing device and method for tissue diagnosis or therapy
US20090036823A1 (en) * 2007-07-30 2009-02-05 Lepivert Patrick Fluid flowing device and method for tissue diagnosis or therapy
US20100274178A1 (en) * 2007-07-30 2010-10-28 Lepivert Patrick Fluid flowing device and method for tissue diagnosis or therapy
AU2017202750B2 (en) * 2007-10-11 2019-05-23 Implantica Patent Ltd. System And Method For Thermal Treatment Of Hypertension, Hypotension Or Aneurysm
WO2009048390A1 (en) * 2007-10-11 2009-04-16 Milux Holding Sa System and method for thermal treatment of hypertension, hypotension or aneurysm
US9968482B2 (en) 2007-10-11 2018-05-15 Peter Forsell System and method for thermal treatment of hypertension, hypotension or aneurysm
US10201413B2 (en) 2009-11-30 2019-02-12 Endospan Ltd. Multi-component stent-graft system for implantation in a blood vessel with multiple branches
US10888413B2 (en) 2009-11-30 2021-01-12 Endospan Ltd. Multi-component stent-graft system for implantation in a blood vessel with multiple branches
US9468517B2 (en) * 2010-02-08 2016-10-18 Endospan Ltd. Thermal energy application for prevention and management of endoleaks in stent-grafts
US20130035751A1 (en) * 2010-02-08 2013-02-07 Endospan Ltd. Thermal energy application for prevention and management of endoleaks in stent-grafts
US20200086108A1 (en) * 2010-08-19 2020-03-19 Electrocore, Inc. Vagal nerve stimulation to reduce inflammation associated with an aneurysm
US20120197244A1 (en) * 2011-01-31 2012-08-02 Cedars-Sinai Medical Center Treatment for aneurysm
US9526638B2 (en) 2011-02-03 2016-12-27 Endospan Ltd. Implantable medical devices constructed of shape memory material
US9486341B2 (en) 2011-03-02 2016-11-08 Endospan Ltd. Reduced-strain extra-vascular ring for treating aortic aneurysm
US20120265188A1 (en) * 2011-04-13 2012-10-18 Cryotherapeutics Gmbh Plaque Stabilisation Using Cryoenergy
US8968282B2 (en) * 2011-04-13 2015-03-03 Cryotherapeutics Gmbh Plaque stabilisation using cryoenergy
US9254209B2 (en) 2011-07-07 2016-02-09 Endospan Ltd. Stent fixation with reduced plastic deformation
US9839510B2 (en) 2011-08-28 2017-12-12 Endospan Ltd. Stent-grafts with post-deployment variable radial displacement
US9427339B2 (en) 2011-10-30 2016-08-30 Endospan Ltd. Triple-collar stent-graft
US9993360B2 (en) 2013-01-08 2018-06-12 Endospan Ltd. Minimization of stent-graft migration during implantation
US9668892B2 (en) 2013-03-11 2017-06-06 Endospan Ltd. Multi-component stent-graft system for aortic dissections
US10603197B2 (en) 2013-11-19 2020-03-31 Endospan Ltd. Stent system with radial-expansion locking
US10485684B2 (en) 2014-12-18 2019-11-26 Endospan Ltd. Endovascular stent-graft with fatigue-resistant lateral tube
US11419742B2 (en) 2014-12-18 2022-08-23 Endospan Ltd. Endovascular stent-graft with fatigue-resistant lateral tube
US10173027B2 (en) 2015-10-07 2019-01-08 Cook Medical Technologies Llc Methods, medical devices and kits for modifying the luminal profile of a body vessel
US10512751B2 (en) 2015-10-07 2019-12-24 Cook Medical Technologies Llc Methods, medical devices and kits for modifying the luminal profile of a body vessel
US11517710B2 (en) 2015-10-07 2022-12-06 Cook Medical Technologies Llc Methods, medical devices and kits for modifying the luminal profile of a body vessel

Also Published As

Publication number Publication date
US7912554B2 (en) 2011-03-22

Similar Documents

Publication Publication Date Title
US7912554B2 (en) Method for treatment of aneurysms
US6736809B2 (en) Method and device for treatment of aneurysms
CA2666334C (en) Endovascular cryotreatment catheter
JP4307081B2 (en) Atrial exfoliation cryogenic balloon
US7022120B2 (en) Cryoplasty device and method
US5971979A (en) Method for cryogenic inhibition of hyperplasia
US6428534B1 (en) Cryogenic angioplasty catheter
US8740891B2 (en) Flexible multi-tubular cryoprobe
KR101832021B1 (en) Plaque stabilisation using cryoenergy
JP5068662B2 (en) Heat treatment technology for varicose veins
US20140323925A1 (en) Methods of delivering energy to body portions to produce a therapeutic response
US20030149368A1 (en) Method and apparatus for locating and detecting vascular plaque via impedence and conductivity measurements, and for cryogenically passivating vascular plaque and inhibiting vascular plaque progression and rupture
JP2004188181A (en) Coaxial catheter system for performing low-temperature ablation in one process
EP3289992A1 (en) Flexible multi-tubular cryoprobe
JP2006524101A (en) Treatment device having a region isolated by an insertion region
JP2004516042A (en) Cryotherapy device and method
JP2011206569A (en) Catheter, apparatus for creating linear ablation and method of ablating tissue
US20090306550A1 (en) Ultrasonic Endometrial Cryoablation Method
US20040249372A1 (en) Method for treatment of aneurysms
US20090299235A1 (en) Ultrasonic Endometrial Cryoablation Device
Sanfelippo Intraoperative Angioscopically Monitored Laser-Assisted Angioplasty in Treating Lower-Extremity Atherosclerotic Occlusive Disease
Akhigbe The Role Of Interventional Radiology In Modern Medical Practice

Legal Events

Date Code Title Description
AS Assignment

Owner name: CRYOCATH TECHNOLOGIES INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CAPUANO, LEONILDA;NAHON, DANIEL;URICK, MICHAEL;AND OTHERS;SIGNING DATES FROM 20050504 TO 20050518;REEL/FRAME:016702/0476

Owner name: CRYOCATH TECHNOLOGIES INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CAPUANO, LEONILDA;NAHON, DANIEL;URICK, MICHAEL;AND OTHERS;REEL/FRAME:016702/0476;SIGNING DATES FROM 20050504 TO 20050518

AS Assignment

Owner name: INVESTISSEMENT QUEBEC,QUEBEC

Free format text: SECURITY INTEREST;ASSIGNOR:CRYOCATH TECHNOLOGIES, INC.;REEL/FRAME:018207/0902

Effective date: 20060717

Owner name: INVESTISSEMENT QUEBEC, QUEBEC

Free format text: SECURITY INTEREST;ASSIGNOR:CRYOCATH TECHNOLOGIES, INC.;REEL/FRAME:018207/0902

Effective date: 20060717

Owner name: INVESTISSEMENT QUEBEC, QUEBEC

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CRYOCATH TECHNOLOGIES, INC.;REEL/FRAME:018207/0902

Effective date: 20060717

AS Assignment

Owner name: CRYOCATH TECHNOLOGIES INC., CANADA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:INVESTISSEMENT QUEBEC;REEL/FRAME:022320/0787

Effective date: 20090220

Owner name: CRYOCATH TECHNOLOGIES INC.,CANADA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:INVESTISSEMENT QUEBEC;REEL/FRAME:022320/0787

Effective date: 20090220

AS Assignment

Owner name: MEDTRONIC CRYOCATH LP, CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CRYOCATH TECHNOLOGIES INC.;REEL/FRAME:023119/0651

Effective date: 20090814

Owner name: MEDTRONIC CRYOCATH LP,CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CRYOCATH TECHNOLOGIES INC.;REEL/FRAME:023119/0651

Effective date: 20090814

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20230322